Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear

This is a one week 2x2 crossover study comparing delefilcon A with etafilcon A, with a primary hypothesis of comparing the handling of each lens. Additional secondary markers are measured looking at subjective comfort and vision of the lenses.

Study Overview

• Status: Completed
• Conditions: Myopia
• Intervention / Treatment: Device: delefilcon A; Device: etafilcon A

• Study Type: Interventional
• Enrollment (Actual): 183
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72116
  • Connecticut
    • Bridgeport, Connecticut, United States, 06610
  • Florida
    • Tampa, Florida, United States, 33625
  • Missouri
    • Blue Springs, Missouri, United States, 64015
  • New York
    • Vestal, New York, United States, 13850
  • North Carolina
    • Raleigh, North Carolina, United States, 27615
  • Pennsylvania
    • Kittanning, Pennsylvania, United States, 16201
  • Rhode Island
    • Warwick, Rhode Island, United States, 02888
  • South Dakota
    • Chamberlain, South Dakota, United States, 57325
  • Tennessee
    • Bartlett, Tennessee, United States, 38134

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The subject must be between 18 and 45 years of age (inclusive) with no presbyopic add.
• The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. This should be recorded on the Case Report Form (CRF).
• The subject must be willing to wear the study lenses for at least 8 hours per day, 7 days per week.
• The subject must be a current successful soft contact lens wearer in both eyes
• The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
• The subject's subjective refraction must result in a vertex corrected spherical contact lens prescription in the range of -1.00D to -6.00D in each eye.
• The subject's refractive astigmatism must be less than or equal to 0.75D in both eyes.
• The subject must have best corrected visual acuity of 20/30 (6/9) or better in each eye.
• The subject must require a visual correction in both eyes (no monofit or monovision allowed).

• The subject must have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:

  1. No amblyopia.
  2. No evidence of lid abnormality or infection (including blepharitis/meibomitis).
  3. No conjunctival abnormality or infection.
  4. No clinically significant slit lamp findings (i.e. stromal edema, vascularization, infiltrates or abnormal opacities).
  5. No other active ocular disease.

Exclusion Criteria:

• Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
• Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
• Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
• Clinically significant (Grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear.
• Any ocular infection.
• Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
• Pregnancy or lactation.
• No extended wear in the last 3 months.
• Diabetes.
• Infectious diseases (e.g. hepatitis, tuberculosis) or an immunosuppressive disease (e.g. HIV).
• Employee or family member of the staff of the investigational site.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Delefilcon A/ Etafilcon A; 6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear	Device: delefilcon A; Daily wear soft contact lens for bilateral distance vision correction use.; Device: etafilcon A; Daily wear soft contact lens for bilateral distance vision correction use.
Experimental: Etafilcon A / Delefilcon A; 6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear	Device: delefilcon A; Daily wear soft contact lens for bilateral distance vision correction use.; Device: etafilcon A; Daily wear soft contact lens for bilateral distance vision correction use.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Subject Reported Ease of Removal	Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant. Outcome is reported as aggregate number of subjects who reported Excellent/Very Good at their 1-week visit.	6-10 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Subject Reported Overall Comfort	Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant. Summary is reported as an aggregate of Excellent/Very Good at their 1-week visit.	6-10 Days
Subject Reported Overall Vision	Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant using an aggregate summary of excellent/very good at their 1-week visit.	6-10 Days
Binocular Snellen Visual Acuity	Snellen visual acuity percentage of eyes with a visual acuity of eyesight testing at a 20/20 level or better by eye.	6-10 Days
Overall Corneal Staining	Proportion of subjects that have corneal staining on the 0-4 the NEI/Industry Workshop guidelines scale, measured by eye. Grade 1 or higher is reported as a percentage of total eyes.	6-10 Days

Collaborators and Investigators

• Sponsor: Johnson & Johnson Vision Care, Inc.

Study record dates

Study Major Dates

• Study Start: August 1, 2012
• Primary Completion (Actual): November 1, 2012
• Study Completion (Actual): November 1, 2012

Study Registration Dates

• First Submitted: August 16, 2012
• First Submitted That Met QC Criteria: August 16, 2012
• First Posted (Estimate): August 21, 2012

Study Record Updates

• Last Update Posted (Actual): June 19, 2018
• Last Update Submitted That Met QC Criteria: June 18, 2018
• Last Verified: March 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Refractive Errors; Myopia
• Other Study ID Numbers: CR-005199